Starpharma Holdings Limited · ASX:SPL
Starpharma — Lux Executive Summit 2006
44 slides from Starpharma's conference presentation, Oct 16, 2006
Slide 1: Starpharma Holdings Limited
Starpharma Holdings Limited ASX:SPL USOTC:SPHRY Lux Executive Summit Cambridge, MA 16 October 2006 Dr Jackie Fairley – CEO “Top “TopNanotech NanotechBuys Buysfor for2005” 2005” “We “Weexpect expectgreat greatthings thingstotocome comefrom fromthe thecompany companyand andits itssignificant significa
Slide 2: Forward-looking statements
This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance that these expectations will prove to be correct. Actual res
Slide 3: Outline
Outline 1. Introduction and Company Overview 2. VivaGelTM – Product Overview and Market Opportunities 3. The Acquisition of DNT 4. Integrated Pipeline 5. Conclusion 3
Slide 4: Company Overview
@ starpharma 1, Company Overview @ starp Larma
Slide 5: Announced October 4, 2006
Announced October 4, 2006 This presentation describes the combined company, in anticipation of the completion of the transaction (expected approx 20 October.) 5
Slide 6: Starpharma Holdings Ltd: Company Overview
Starpharma Holdings Ltd: Company Overview Headquartered in Melbourne, Australia ASX Listed ASX:SPL ; 9.7% issued capital via USOTC:SPHRY World leader in the development of dendrimer nanotechnology products for pharmaceutical and life-sciences Starpharma’s lead product, VivaGel™ is being deve
Slide 7: Starpharma: 05/06 Highlights
Starpharma: 05/06 Highlights HIV Funded: A$26 million NIH funds VivaGel™ HIV development with non-dilutive funding Genital Herpes Funded NIH funds VivaGel™ Genital Herpes Development HIV Fast Tracked US regulator FDA designated VivaGel™ a fast track product Herpes IND Cleared FDA clears VivaGel™ Gen
Slide 8: Starpharma: Share Price History
Starpharma: Share Price History 14 Nov 05: 3 Oct 05: SPL raises A$15M 20 Apr 06: 24 Aug 06: SPL announces through an NIH funds clinical Commences safety Share Price ($) US$20.3M funding institutional development of trial for Vivagel in from NIH for to placement & SPP VivaGel for genital men accelera
Slide 9: Shareholder Composition and Financial Statistics
Shareholder Composition and Financial Statistics Starpharma Holdings Limited Post DNT Transaction Shareholder Register ASX Code: SPL Dow US 8.6% Level 1 ADR Code: SPHRY Investors Shares on Issue: 167.8M 10.2% Market Cap: ~ A$85M (US$65M) Share Price: A$0.51 Retail 12 Month High/Low: A$0.67 / A$0.35
Slide 10: Starpharma: Technology Overview
Starpharma: Technology Overview Unique Characteristics of Dendrimers: Precisely defined, synthetic macromolecules (1- 10nm, 5-50kD) Precisely defined surface topology Can be designed to optimize potency, pharmacokinetics and localization Different species can be heat stable or biodegradable
Slide 11: 2. VivaGel - Product Overview
2. VivaGelTM Product Overview
Slide 12: VivaGel - Lead Product for Prevention of STIs
VivaGelTM – Lead Product for Prevention of STIs VivaGelTM packaged into pre-filled applicators. VivaGelTM is a microbicide being developed to prevent sexually transmitted infections (STIs) in women VivaGelTM is a gel-based formulation with a nanotech active, delivered privately via an applicator
Slide 13: HIV - A Preventable, Life Threatening Disease
HIV – A Preventable, Life Threatening Disease Human Immunodeficiency Virus (HIV) is the virus that causes AIDS (Acquired Immune Deficiency Syndrome) No cure for HIV/AIDS and may be transmitted by individuals that are asymptomatic 39 million people living with HIV; every day 7,000 women are new
Slide 14: Genital Herpes - Nasty, Incurable Disease
Genital Herpes – Nasty, Incurable Disease Genital herpes is the “un-recognised pandemic” of the industrialised world – 22% of the US adult population has genital herpes; Est. cost (US) >$1.5B pa – Without intervention the prevalence of genital herpes in the US is expected to increase to 39% of men
Slide 15: VivaGel - Product Features and Performance
VivaGelTM – Product Features and Performance Product Offers Market research indicates microbicide gels will have good uptake Several Key Female controlled, PEL discreet and convenient Advantages Compelling competitive advantages: efficacy; non-irritant; broad activity Contraceptive activity (in anim
Slide 16: Commercial Opportunity for Microbicides
Commercial Opportunity for Microbicides Large, addressable markets: “If I had a magic bullet to accelerate something it would – HIV primarily in developing countries be the microbicide…..” – HSV-2 in both developing and developed countries Bill Gates, Increasing market “pull’ for products July 2
Slide 17: VivaGel: Summary
VivaGel™ : Summary Topical microbicide gel with nanotech (dendrimer) active being developed under 2 INDs for the prevention of: – HIV and Genital Herpes Compelling competitive advantages: efficacy; non-irritant; broad activity* Successfully completed Phase 1 trial in Humans Further human stu
Slide 18: 3. The Acquisition of DNT
@ starpharma 3.The Acquisition of DNT @ starp Larma
Slide 19: Transaction Overview
Transaction Overview Prior to transaction: Starpharma had a 33% equity holding in the Michigan based private company Dendritic Nanotechnologies Inc (DNT) Transaction: Starpharma is acquiring the remaining 67% of DNT for ~US$6.97 million worth of SPL shares DNT is a leader in the development of
Slide 20: Overview of DNT Inc.
Overview of DNT Inc. DNT is a leading developer and provider of advanced dendritic polymers – headquartered in Michigan and currently employs 16 (13 Ph.Ds) DNT has existing revenues streams from deals with leading pharmaceutical and biotechnology companies including Dade Behring Inc and Qiagen G
Slide 21: Significant Acquisition Benefits
Significant Acquisition Benefits Marketed products, near-term revenues 1. Diversified Product Portfolio Diversified risk: “more shots on goal” Optimal leverage of internal resources including 2. Significant Development and commercial, regulatory, scale-up and discovery Commercialisation Synerg
Slide 22: Post Transaction Company Structure
Post Transaction Company Structure Starpharma 8.6% Holdings Limited ASX:SPL USOTC:SPHRY Dendritic Nanotechnologies Starpharma Pty Ltd Inc. Mount Pleasant, Michigan Melbourne, Australia ~16 Employees ~36 employees * Acquisition of DNT announced 4 October 2006, Completion expected 20 October222006
Slide 23: Integrated Pipeline
@ starpharma 4, Integrated Pipeline @ starp Larma
Slide 24: Integrated Pipeline: Balanced for Risk
Integrated Pipeline: Balanced for Risk Multiple Near-Term Future High-Value Commercial Commercial Opportunities Opportunities Industrial Products Life-science Applications Pharmaceutical Products Research Research Drug Drug VivaGel™ VivaGel™ Reagents Reagents Optimisation Optimisation Industrial Ind
Slide 25: Integrated Pipeline: Balanced for Risk
Integrated Pipeline: Balanced for Risk Pharmaceutical & Medical Products Proof of Concept Lead Clinical Trials Sales VivaGel™ ► HSV-2 prevention ► HIV prevention ► condoms coating & other line extensions ADME Engineering™ ► Therapeutic protein PK optimisation Drug Delivery - Small Molecules ► Cancer
Slide 26: Pipeline: Marketed Dendrimer Products
Pipeline: Marketed Dendrimer Products DNT has product sales and licensed dendrimer royalty agreements Stratus CS® : Cardiac marker diagnostic licensed to Dade Behring, leading diagnostic company SuperFect® : Gene transfection technology licensed to Qiagen, #1 supplier of niche molecular biology
Slide 27: Pipeline: PrioFect siRNA transfection agents
Pipeline: PrioFect™ siRNA transfection agents Transfection reagent sales : $120 million in 2004, growing by 15-18% pa1 PrioFect™ siRNA Transfection Reagents provide: – Precise size control: allows optimisation according to cell type – Highly functionalised surface: allows targeting to specific c
Slide 28: Pipeline: Drug Delivery / Optimisation / PK Modification
Pipeline: Drug Delivery / Optimisation / PK* Modification *PK: pharmacokinetics 28
Slide 29: Pipeline: Drug Delivery / Optimisation / PK Modification
Pipeline: Drug Delivery / Optimisation / PK Modification Plasma concentration-time profile in male SD rats for PEGylated poly-L-lysine dendrimers 100000 plasma dendrimer (ng equiv/ml) O O Lys16(PEG2000)32 O O t½ = 0.6h O O O O Therapeutic Protein O O 10000 t½ = 0.7h O O N N N N O N O N t½ = 9.5h O O
Slide 30: Pipeline: Materials Science / Industrial Applications
Pipeline: Materials Science / Industrial Applications Sector Discussions with… Application Oil "Top 5" US Oil Company Lubricant additives Plastics Large Automotive Components Plastics additive Manufacturer Manufacturing Major Technology Company Dental resins Multiple avenues of exploration Adhesives
Slide 31: Partners
Partners Industry Collaborators Research/Uni. Collaborators 31
Slide 32: 5. Conclusion
@ starpharma 5. Conclusion @ starp Larma
Slide 33: Starpharma: Investment Highlights (post-transaction)
Starpharma : Investment Highlights (post-transaction) >US$26m* non-diluting funding from the NIH for lead development VivaGel™ - the only microbicide with NIH funding for genital herpes Significant US shareholder base and profile: The Dow Chemical Company largest shareholder (8.6%) Success
Slide 34: Further Information
Further Information: Web: www.starpharma.com Email: jackie.fairley@starpharma.com Phone: + 613 8532 2704
Slide 35: Supplementary Material
@ starpharma Supplementary Material @ starp Larma
Slide 36: VivaGel: Significant Advantages Over Competitors
VivaGelTM : Significant Advantages Over Competitors Competitor Category Key Disadvantages VivaGelTM Advantages VivaGel™ is the only microbicide being developed to prevent HSV -2 genital herpes Ulceration possible; potential No surfactant properties; Surfactants/ Detergents incr. risk of HIV infe
Slide 37: VivaGel: NIH support (HIV and HSV-2) & FDA Fast Track
VivaGel™: NIH support (HIV and HSV-2) & FDA Fast Track Funding is provided without downstream commercial obligations > US$20.3m of non- dilutive funding from Funding will allow Starpharma to do a late-stage licensing deal and NIH thus secure advantageous terms NIH funding will support VivaGel’
Slide 38: VivaGel: Potent Contraceptive Activity in Rabbits
VivaGel™ : Potent Contraceptive Activity in Rabbits Recent study has shown that SPL7013, the active ingredient in its VivaGel™, exhibits a potent contraceptive effect in rabbits Independent study undertaken at Johns Hopkins University under an NIH grant Fertility was reduced by more than 75% b
Slide 39: VivaGel - Excellent Market Opportunities
VivaGelTM – Excellent Market Opportunities Estimated Market for microbicides in Developed Countries: Average Frequency of Use per Annum Market Penetration 25x 50x 100x 2.5% US$365m US$730m US$1460m 5.0% US$725m US$1450m US$2900m 10.0% US$1450m US$2900m US$5800m Key assumptions – 291m women of reprod
Slide 40: Transaction Details
Transaction Details Starpharma to acquire the remaining 67% equity in DNT that it does not already own for new shares in Starpharma valued to ~US$6.97 million Transaction is subject to shareholder approval in majority of each DNT share class – Between then Dow and SPL hold the majority in each c
Slide 41: Extensive IP Portfolio
Extensive IP Portfolio DNT owns the most significant dendrimer IP portfolio as a result of the assignment of Dow’s dendrimer IP portfolio in 2005 “When “Whenititcomes comesto topharmaceutical pharmaceuticalapplications, applications,many manyrelevant relevantpatents patentsare areunder under the t
Slide 42: Pipeline Management
Pipeline Management Development approach Starpharma StarpharmaProduct Product Starpharma Starpharma Development Development resource resource Mitigated by external demand demand funding sources, e.g. e.g. NIH $20m e.g.VivaGel™, VivaGel™, High PrioFect™ High PrioFect™ Starpharma: Starpharma:base base
Slide 43: DNT: Targeted Cancer Diagnostic
DNT: Targeted Cancer Diagnostic DNT is developing a Priostar™ dendrimer-based , receptor-targeted diagnostic and therapeutic technology for the early detection and treatment of ovarian cancer Unique technology: – Priostar™ dendrimer targeted delivery system will be combined with a magnetic reson
Slide 44: DNT: Specialty Commercial Products
DNT: Specialty Commercial Products Priostar™ and STARBURST® dendrimers commercially available Priostar™ family of dendrimers have advantageous properties over other nanostructures Attractive Product Characteristics: – New Functionality and Improved Properties – Efficient & Scalable Manufacturi